We demonstrated that Renifolin F attenuated allergic inflammation in an OVA-induced allergic asthma mice model in vivo, and the activity of Renifolin F was assessed through inhibiting the regulation of ILC2s in the lung, including inhibition of the upstream cytokines of ILC2s (such as IL-25, IL-33 and TSLP) and the downstream cytokines of ILC2s (such as IL-4, IL-5, IL-9 and IL-13), subsequently reducing the content of IL-2 and IL-7, which are co-stimulatory factors that activate ILC2s. Here, IL4 is linked to allergic asthma.